Hospital Universitari Dexeus - Grupo Quironsalud

Barcelona 08028

2 studies enrolling now · 7 studies all time

What they study most

Colorectal Cancer, Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, HER2 Amplification, HER2 Positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Metastatic Breast Cancer

Studies at this site

• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer — Recruiting now
• First-in-Human Study of TAK-280 in Participants With Solid Tumors — Stopped early
• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Completed
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer — Running, not enrolling
• Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence — Stopped early